United Kingdom · Delayed Price · Currency is GBP · Price in USD BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of GBP 16.16 billion. The enterprise value is 4.87 billion.
| Market Cap | 16.16B |
| Enterprise Value | 4.87B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.29% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 16.22% |
| Owned by Institutions (%) | 19.52% |
| Float | 106.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.91 |
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.55, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.55 |
| Quick Ratio | 7.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -92.55 |
Financial Efficiency
Return on equity (ROE) is -8.14% and return on invested capital (ROIC) is -29.88%.
| Return on Equity (ROE) | -8.14% |
| Return on Assets (ROA) | -4.04% |
| Return on Invested Capital (ROIC) | -29.88% |
| Return on Capital Employed (ROCE) | -7.32% |
| Weighted Average Cost of Capital (WACC) | 11.42% |
| Revenue Per Employee | 265,176 |
| Profits Per Employee | -161,409 |
| Employee Count | 7,807 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 3.88 |
Taxes
In the past 12 months, BioNTech SE has paid 35.07 million in taxes.
| Income Tax | 35.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.13% in the last 52 weeks. The beta is 1.33, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -13.13% |
| 50-Day Moving Average | 94.32 |
| 200-Day Moving Average | 96.07 |
| Relative Strength Index (RSI) | 41.12 |
| Average Volume (20 Days) | 5,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.86 |
Income Statement
In the last 12 months, BioNTech SE had revenue of GBP 2.07 billion and -1.26 billion in losses. Loss per share was -5.01.
| Revenue | 2.07B |
| Gross Profit | 1.59B |
| Operating Income | -1.15B |
| Pretax Income | -1.23B |
| Net Income | -1.26B |
| EBITDA | -869.30M |
| EBIT | -1.15B |
| Loss Per Share | -5.01 |
Balance Sheet
The company has 11.72 billion in cash and 307.76 million in debt, with a net cash position of 11.41 billion.
| Cash & Cash Equivalents | 11.72B |
| Total Debt | 307.76M |
| Net Cash | 11.41B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.15B |
| Book Value Per Share | 61.11 |
| Working Capital | 11.84B |
Cash Flow
In the last 12 months, operating cash flow was -197.42 million and capital expenditures -178.09 million, giving a free cash flow of -375.50 million.
| Operating Cash Flow | -197.42M |
| Capital Expenditures | -178.09M |
| Depreciation & Amortization | 272.52M |
| Net Borrowing | 64.01M |
| Free Cash Flow | -375.50M |
| FCF Per Share | n/a |
Margins
Gross margin is 76.73%, with operating and profit margins of -55.45% and -60.87%.
| Gross Margin | 76.73% |
| Operating Margin | -55.45% |
| Pretax Margin | -59.17% |
| Profit Margin | -60.87% |
| EBITDA Margin | -41.99% |
| EBIT Margin | -55.45% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.29% |
| Shareholder Yield | -4.29% |
| Earnings Yield | -7.68% |
| FCF Yield | -2.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 7.02 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.02 |
| Piotroski F-Score | 2 |